CGT-6737 / Cogent Biosci - LARVOL DELTA

Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) - "Cogent Biosciences...announced the addition of a potent and selective KRAS inhibitor to its pipeline. Preclinical data from this program...will be presented...at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics....The poster presented today describes Cogent’s internally-developed pan KRAS(ON) inhibitor with selectivity over HRAS and NRAS and picomolar (pM) activity across KRAS mutations without the potential liabilities of molecules in the class. Following oral administration, CGT6737 demonstrated robust PK/PD and tumor growth inhibition with 90% PD inhibition in mouse xenograft models."

Pipeline update • Preclinical • Solid Tumor